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Abstract
Background: In the initial absence of specific reversal agents for factor Xa inhibi-
tors (FXa-Is), prothrombin complex concentrate (PCC) as a hemostatic agent has 
been recommended by guidelines. Since 2017, idarucizumab has been registered for 
dabigatran reversal. Still, data on the clinical outcome of direct oral anticoagulant 
(DOAC)-related emergencies (major bleeding or urgent interventions) is scarce. In 
addition, it is unknown to what extent PCC restores thrombin generation in FXa-I–
related emergencies. Our aim was to describe management and clinical outcomes of 
DOAC-related emergencies and to assess the laboratory effect of PCC in patients 
with FXa-I emergencies.
Methods: In this prospective cohort study in 5 Dutch hospitals, patients presenting 
with DOAC-related emergencies were eligible. The primary outcome was effective 
hemostasis according to the ISTH definition. Safety outcomes were 30-day mortal-
ity and thromboembolic rate. In patients treated with PCC, additional blood samples 
were taken to assess the effect on thrombin generation.
Results: We included 101 patients with major bleeding (FXa-I, 76; dabigatran, 25) 
and 21 patients requiring an urgent intervention (FXa-I, 16; dabigatran, 5). Of pa-
tients with major bleeding, 67% were treated with PCC or idarucizumab. Effective 
hemostasis, 30-day mortality, and thromboembolism rate were 67%, 22%, and 1%, 
respectively. In a subset of bleeding patients on FXa-I managed with PCC, thrombin 
generation increased, with 96% immediately after PCC administration. In patients 
requiring an urgent intervention, effective hemostasis, 30-day mortality, and throm-
boembolic rate were 95%, 14%, and 5%.
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Essentials
• In 121 direct oral anticoagulant–related emergencies, two thirds of patients achieved effective hemostasis.
• In those with life-threatening FXa inhibitor–related bleeding, effective hemostasis was 70% when PCC was used.
• This study demonstrates that PCC swiftly restores thrombin generation in bleeding patients on FXa inhibitors.
• The hemostatic efficacy achieved by PCC seems comparable to that achieved by andexanet alfa, and therefore a randomized comparison 
would be valuable.
1  | INTRODUCTION
Worldwide, millions of patients with atrial fibrillation (AF) and ve-
nous thromboembolism (VTE) as primary indications are treated 
with oral anticoagulant agents. While highly effective, the benefit of 
oral anticoagulation is partly offset by the risk of bleeding complica-
tions. The incidence of major bleeding while on oral anticoagulation 
is estimated at 2%-3% per year with a case fatality rate of 7.6% (95% 
confidence interval [CI], 6.5%-8.7%) for direct oral anticoagulants 
(DOACs) and 11% (95% CI, 9.2%-13.1%) for vitamin K antagonist 
(VKA)-related bleeding.1-6
Currently, the DOACs apixaban, dabigatran etexilate (dabiga-
tran), edoxaban, and rivaroxaban are replacing VKAs in the majority 
of patients with AF and VTE.7 Compared with VKAs, DOACs are at 
least as effective in preventing thromboembolic events, while the 
risk of major bleeding complications differs; in comparison with 
VKAs, DOACs reduce the risk of intracranial hemorrhage (ICH) and 
fatal bleeding by 50% and increase the risk of gastrointestinal bleed-
ing by 25%.1,8,9 Consequently, international guidelines recommend 
DOACs over VKAs for patients with AF and VTE.10,11Nevertheless, 
due to the vast numbers of patients on long-term oral anticoagula-
tion, DOAC-related major bleeding is still encountered frequently, 
and optimal management of these patients is paramount to prevent 
permanent disabilities and death.
One aspect of the management of patients with a major bleed-
ing is to restore functional hemostasis by rapidly reversing the ef-
fects of the anticoagulant. However, upon registration of the first 
DOAC in 2008, no specific reversal agent was available, which led 
to considerable concern on the safety of DOACs, especially for pa-
tients deemed to be at the highest risk of bleeding.12 Idarucizumab, 
a high-affinity antibody specific for dabigatran, was approved for 
emergency reversal of dabigatran in patients with major bleeding 
or urgent interventions a few years later.13 For the reversal of the 
direct factor Xa inhibitors (FXa-Is) apixaban and rivaroxaban for 
major bleeding, the US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) have recently approved andex-
anet alfa.14 Andexanet alfa is neither approved for reversal of the 
FXa-Is edoxaban and betrixaban, nor is it approved for reversal in 
nonbleeding patients requiring an urgent intervention. Prior to the 
regulatory approval of idarucizumab and andexanet alfa, interna-
tional guidance documents recommended the use of 4-factor pro-
thrombin complex concentrate (PCC) at a dose of 25-50 IU/kg for 
DOAC-related life-threatening situations.15 These recommendations 
were largely based on crossover studies, demonstrating that PCC in 
a dose of 50 IU/kg swiftly restored endogenous thrombin potential 
(ETP) to pre-anticoagulant levels in healthy volunteers treated with 
FXa-Is.16-19 Major bleeding itself, however, causes systemic coagula-
tion activation to achieve hemostasis. Therefore, the overall effect of 
PCC might be different in bleeding versus nonbleeding patients. To 
our knowledge, no study has thus far evaluated the effects of PCC on 
coagulation parameters in patients that present with bleeding.
Studies evaluating the clinical management and outcome of pa-
tients presenting with a DOAC-related emergency are scarce. In a 
recently published meta-analysis of 10 single-arm case series con-
sisting of 340 patients treated with PCC for FXa-I–related major 
bleeding, hemostasis was achieved in the majority of patients.20 
However, these studies were quite heterogeneous with respect to 
eligibility criteria, follow-up period, and definition of outcomes, in-
cluding hemostasis. Only 2 studies evaluated effective hemostasis 
according to the ISTH definition.21,22 These criteria for hemostatic 
efficacy were developed in conjunction with the FDA for the trial 
that led to regulatory approval of PCC for management of VKA-
related emergencies in the United States.23 According to these cri-
teria, hemostasis can be classified as excellent, good, or poor, with 
different criteria for different sites of bleeding (musculoskeletal, 
intracranial, or other nonvisible bleeding), wherein effective hemo-
stasis is defined as either excellent or good hemostasis. This scoring 
system has undergone minor modifications and is frequently used 
Conclusions: Effective hemostasis was achieved in the majority of patients present-
ing with DOAC-related emergencies;, thromboembolic complications were rare, and 
mortality was quite high.
K E Y W O R D S
dabigatran, emergencies, factor Xa inhibitors, hemorrhage, idarucizumab, prothrombin 
complex concentrates
     |  571BAVALIA et AL.
in contemporary reversal studies evaluating the outcome of bleed-
ing on anticoagulant therapy.24 Even though there is an acknowl-
edged definition for effective hemostasis, interpretation of data 
on efficacy of reversal agents remains a challenge due to the lack 
of placebo-controlled arms. Therefore, it is uncertain if hemostatic 
therapies over supportive management have additional benefit. As 
providing a placebo control group in this study subject is unethical 
and probably will never be conducted, we believe it is of great im-
portance to provide more data on this topic from different countries 
and settings worldwide to gain more insight on the interpretation of 
the single-arm studies data.
The primary aim of this study was to describe the management 
and outcome of DOAC-related emergencies in terms of effective he-
mostasis according to the criteria of the ISTH and to evaluate effective 
hemostasis and risk of thromboembolic events in those patients who 
were treated with PCC. The secondary aim was to evaluate the ef-
fects of PCC on coagulation parameters in actively bleeding patients.
2  | METHODS
2.1 | Study design and population
We conducted a multicenter, prospective cohort study evaluating the 
clinical management of DOAC-related emergencies from December 
2014 up until December 2018. Consecutive patients were enrolled 
in 5 Dutch hospitals (4 academic and 1 teaching hospital). The ethics 
committee of Amsterdam Medical Center approved the study pro-
tocol. Patients were eligible for participation if they were 18 years 
or older, received treatment with a DOAC (apixaban, dabigatran, 
edoxaban, rivaroxaban) for any indication, and presented with a 
DOAC-related emergency, that is, major bleeding or the need for 
an urgent intervention within the next 8 hours. Major bleeding was 
defined as any bleeding resulting in death; symptomatic bleeding in 
a critical organ (intracranial, intraspinal, intraocular, retroperitoneal, 
intra-articular, and pericardial bleeding and muscle bleeding result-
ing in compartment syndrome) or symptomatic bleeding resulting 
in a decrease in the hemoglobin concentration of at least 2 g/dL 
(1.2 mmol/L) or resulting in transfusion of at least 2 units of eryth-
rocytes, following the ISTH criteria.25 Eligibility was adjudicated by 
the local coordinators in every medical center and reevaluated by 
the national coordinator in the Amsterdam UMC. If in doubt, a third 
author (MC) was involved in assessing eligibility.
In patients who met the criteria for ISTH major bleeding, bleed-
ing was further subclassified according to the severity of the clinical 
presentation and course, using a previously established scoring sys-
tem, which is shown in Table 1.26 Urgent interventions were defined 
as any nonbleeding emergency situations in which an intervention 
was indicated within 8 hours. We categorized the urgent interven-
tions in situations leading to a procedure in the operating theater 
(surgery) and situations that did not (other procedures).
Patients participating in trials evaluating efficacy and safety of 
other investigational products were excluded. The treatment and 
management of the DOAC-related emergency was at the discretion of 
the treating physician, and therefore follow-up of the emergency was 
not protocolled. Any interventions to control bleeding and periopera-
tive strategies were recorded but not part of the study protocol. We 
collected data of the included patients within 48 hours of presentation 
by reviewing the electronic patient chart and by a clinical or telephone 
visit for the patients who gave consent. In case of uncertainties, we 
obtained additional information from the treating physicians, the pa-
tient, patient’s representatives, or the general practitioner.
Patients underwent additional blood draws at presentation (T0) 
and 4-8 hours after presentation (T2). In patients who received PCC 
for the FXa-I–related emergency, samples were drawn 15-30 min-
utes after administration of PCC (T1). In patients undergoing addi-
tional blood draws, we obtained written informed consent. Patients 
were followed until 30 days after inclusion or death.
2.2 | Outcomes
2.2.1 | Hemostatic efficacy
The primary clinical outcome in patients presenting with a DOAC-
related bleeding was effective hemostasis at 24 hours after pres-
entation, according to the ISTH definition.23,24 We assessed ICH by 
the ISTH definition and non-ICH by the original criteria by Sarode at 
24 hours.23,24 As effective hemostasis was evaluated up to 24 hours 
only, we considered rebleeding events after 24 hours until 30 days as 
a secondary efficacy outcome. For patients presenting with the need 
for an acute urgent intervention, we defined (surgical) hemostasis as 
effective when no major bleeding occurred within 7 days after the 
urgent intervention.27 We defined poor hemostasis if a major bleed-
ing occurred within 7 days after the urgent intervention. We chose 
this cutoff as we thought of 7 days being the most clinically relevant 
period. Hemostatic efficacy was assessed by the local coordinators 
in every center and reevaluated by the national coordinator in the 
Amsterdam UMC. If in doubt, a third author (MC) was involved in 
assessing hemostatic efficacy.
TA B L E  1   Established scoring system for major bleeding 
according to the severity of the clinical presentation
Category Description
1 Bleeding events presenting without any clinical 
emergency
2 All bleeding events that could not be classified to 
any of the other 3 categories, as they presented 
with the need for some measures but without 
clear urgency
3 Bleeding events presenting with great medical 
emergency, eg, with hemodynamic instability, 
or cerebral major bleeding presenting with 
neurological symptoms
4 Bleeding events already fatal before or almost 
immediately upon entering the hospital
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2.2.2 | Safety outcomes
Safety outcomes consisted of arterial (acute coronary syndrome, 
stroke, transient ischemic attack, or systemic embolism) and venous 
thromboembolism (pulmonary embolism, deep vein thrombosis) and 
mortality up to 30 days after presentation with the emergency.
2.3 | Laboratory assays
We determined FXa-I and dabigatran levels using Biophen direct factor 
Xa and Hemoclot direct thrombin inhibitor assay kits (Hyphen Biomed) 
with apixaban, dabigatran, edoxaban, and rivaroxaban calibrators and 
control plasma (Hyphen Biomed) where appropriate. We performed 
thrombin generation (calibrated automated thrombography [CAT] 
method) as per manufacturer's instruction (Thrombinoscope Stago) 
with some minor modifications. Final plasma concentration was 50% 
v/v (60 µL of plasma, 20 µL of buffered saline, 20 µL of calibrator or 
PPP reagent, 20 µL of FluCa). Calibrator and PPP reagent (5 PM tis-
sue factor) were from Thrombinoscope. FluCa was a 3-mM mixture 
of the fluorogenic thrombin substrate z-Gly-Gly-Arg-AMC (Bachem) 
in 90 mM of CaCl2. To eliminate calibrator inhibition during measure-
ment, dabigatran-containing samples were treated with DOAC Stop 
(Haematex Research) before applying to the calibrator wells as de-
scribed before.28 We used optical density tracings of fibrin formation 
and clot lysis performed in 96-well microplates (fibrin generation and 
clot lysis test) to determine plasma clotting time (CT) and clot lysis time 
(CLT) as described previously.29 Briefly, 75 µL of plasma was mixed 
with 75 µL of start reagent (tissue factor, phospholipids, tissue plas-
minogen activator, and CaCl2 at final concentrations of 0.5 PM, 4 µM, 
50 ng/mL, and 15 mM, respectively) and optical density (405 nM) re-
corded for 3 hours at 37°C. Start reagent mixture was prepared from 
commercially obtained ingredients as described.29 During measure-
ment, we sealed plates to avoid sample dehydration. The first part 
of the tracing represents fibrin clot formation. We defined CT as the 
time from reagent addition to half maximal optical density. The sec-
ond part of the tracing with a decline from maximal to baseline optical 
density represents clot lysis. We defined CLT as the time between CT 
and half-maximal lysis. CLT was abrogated in samples from patients 
on tranexamic acid (CLT > 3 hours). To establish in-house reference 
ranges, we determined thrombin generation parameters, CT and CLT 
in nonanticoagulated healthy volunteers (n = 40 for thrombin genera-
tion and n = 24 for the fibrin generation and clot lysis test). Male and 
female donors aged between 20 and 65 and were randomly selected.
2.4 | Statistical analysis
We described continuous variables by central tendency and vari-
ability according to the distribution and categorical variables as pro-
portions. We calculated CIs for the primary and safety outcomes 
using the Wilson method. For comparison of the coagulation pa-
rameters of the plasma of the patients at T0 with the plasma of the 
healthy volunteers, we performed the Mann-Whitney U test. For 
comparison of the intraindividual coagulation parameters over time 
points T0 and T1, we performed a paired t-test analysis. Differences 
in laboratory values between the group of patients who did achieve 
effective hemostasis and the group who did not achieve effective 
hemostasis were evaluated using the Mann-Whitney U test.
3  | RESULTS
3.1 | Major bleeding
We included 101 patients with major bleeding with a mean age of 
75 years (Table 2). Rivaroxaban was the DOAC that was most frequently 
used (54%) and the median (interquartile range [IQR]) time since last 
DOAC intake 10 (6-16) hours. The most common site of bleeding was 
intracranial (59%), followed by gastrointestinal (27%). Table 3 presents 
the severity of presentation and course of the 101 patients with major 
bleeding, stratified for FXa-I and dabigatran. The majority of patients 
(77%) presented with a category 3 bleeding, which signifies major 
bleeding presenting with great medical emergency.26 Of 101 patients, 
68 (67%) received a PCC or idarucizumab. In the remaining 33 patients, 
no PCC or idarucizumab was administered. Of those, 4 patients were 
considered as a category 4 bleeding, indicating that death was imminent 
and no lifesaving measures were undertaken, 11 patients were consid-
ered as category 1 or 2, in which the treating physician deemed the 
bleeding not severe enough to warrant urgent hemostatic measures, 
and 18 in category 3, in which the treating physician decided to take 
urgent measures (eg, multiple transfusion units, procedures to achieve 
local hemostasis) but without administration of PCC or idarucizumab.
In total, 68 (67%; 95% CI, 58%-76%) achieved effective hemo-
stasis. Twenty-two (22%; 95% CI, 15%-31%) patients died within 
30 days, and in 18 of the 22 patients the cause of death was the 
initial bleed (17 ICH and 1 peritoneal bleed). Two patients died due 
to an underlying malignancy, 1 patient died due to multiorgan fail-
ure, and in 1 patient the cause was unknown but autopsy showed 
advanced liver cirrhosis and pulmonary congestion. No patients died 
of thromboembolic complications. One (1.0%; 95% CI, 0.2%-5.4%) 
thromboembolic event occurred during the 30-day follow-up period.
3.1.1 | FXa-I–related major bleeding
A total of 76 patients presented with a FXa-I–related major bleeding, 
of whom 51 (67%) received PCC as a hemostatic agent (Table 3). One 
patient was mistakenly thought to have a dabigatran-related bleed-
ing, whereas he had a rivaroxaban-related bleeding and therefore 
first received idarucizumab, immediately followed by PCC after it 
was learned the patient was on rivaroxaban. The median total dose 
of administered PCC per patient was 3500 IU (IQR, 3000-4000 IU), 
corresponding with 50 IU/kg (IQR, 46-50 IU).
Hemostatic efficacy at 24 hours was not assessable in 5 (10%) 
patients who received PCC due to immediate transfer to another 
     |  573BAVALIA et AL.
hospital. However, these patients did complete follow-up visits at 
30 days by chart review or by telephone. Effective hemostasis was 
achieved in 32 (70%; 95% CI, 55%-81%) patients (Table 4). Nine 
(18%; 95% CI, 10%-30%) patients died within 30 days, and 1 (2.0%; 
95% CI, 0.3%-10%) patient developed a thromboembolic event. The 
thromboembolic event was a nonfatal pulmonary embolism, which 
occurred 10 days after admission in a woman who had been using 
rivaroxaban for AF and who had been simultaneously treated with 
fresh frozen plasma, packed cells, and 2 units of platelet transfusions 
and in whom anticoagulation had not yet been resumed. Rebleeding 
at the initial bleeding site occurred in 4 patients on days 5, 10, 13, 
and 24, respectively, 1 of which was provoked by a new head trauma. 
It is unknown if anticoagulation had been resumed in these patients.
Of the remaining 25 patients with major bleedings who did not 
receive PCC, effective hemostasis was achieved in 16 of the 25 pa-
tients (64%; 95% CI, 45%-80%). At 30 days, 7 (28%; 95% CI, 14%-
48%) patients had died and no thromboembolic events occurred.
3.1.2 | Dabigatran-related major bleeding
A total of 25 patients presented with dabigatran-related major bleed-
ing, and 16 (64%) of those patients received idarucizumab as a re-
versal agent (Table 3). Two patients also received PCC as part of the 
reversal strategy and 1 patient received only PCC as a reversal agent 
in a dose of 50 IU/kg. The median total dose of administered idaruci-
zumab was 5 g. Effective hemostasis was achieved in 12 (75%; 95% CI, 
51%-90%) patients treated with idarucizumab. The patient who had 
received PCC as a single reversal agent, had presented with intracer-
ebral bleeding, was rated as poor hemostasis and passed away within 
1 day at the hospital. Of the 16 patients, 3 passed away within 30 days 
(18%; 95% CI, 6%-41%) and no thromboembolic events occurred.
In the 8 patients who did not receive idarucizumab, effective he-
mostasis was achieved in 4 (50%; 95% CI, 22%-79%), and 3 (38%; 
95% CI, 14%-70%) died within 30 days (Table 4).
3.2 | Urgent interventions
We included 21 patients who required to undergo an urgent interven-
tion while on DOAC therapy. Mean (SD) age was 70 (12) years, rivaroxa-
ban was the most commonly used DOAC (43%) (Table 2). The median 
(IQR) time since last DOAC intake was 10 (8-18) hours. The urgent in-
tervention was a surgery in the operation theater in 11 patients (52%); 
the remainder underwent other invasive procedures such as chest 
tube placements (n = 4), nephrostomies (n = 2), lumbar puncture (n = 1), 
placement of suprapubic catheter (n = 1), and coiling of a chronic hema-
toma that had occurred after a shoulder fixation. In 19 (90%) patients, 
PCC or idarucizumab was administered before the urgent intervention 
(Table 5), and 2 (10%) patients did not receive PCC or idarucizumab. 
Surgical effective hemostasis was achieved in 20 patients (95%; 95% 
CI, 77%-99%). In the urgent intervention group, 3 patients (15%; 95% 
CI, 5%-36%) passed away within 30 days. Two patients died due to an 
underlying sepsis, and 1 patient died due to an ischemic stroke. One 
(5%; 95% CI, 1%-23%) thromboembolic event occurred in 1 patient.
3.2.1 | Urgent intervention while on FXa-I
A total 16 of the 21 patients (76%) presented with an indication for 
urgent intervention while on a FXa-I , of whom 14 (88%) received 






Age, y, mean (SD) 75 (11) 70 (12)
Male sex, n (%) 59 (58) 17 (81)
Weight, kg, mean (SDa  77.7 (16) 81.7 (23)
eGFR, n (%)b 
>60 mL/min 12 (63) 59 (60)
30-60 mL/min 4 (21) 33 (34)
<30 mL/min 3 (16) 6 (6)
Indication DOAC, n (%)
Atrial fibrillation 85 (87) 18 (86)
Venous 
thromboembolism
12 (12) 3 (14)
Other 1 (1) 0
Unknown 3 (3) 0
DOAC type, n (%)
Apixaban 16 (16) 5 (24)
Dabigatran 25 (25) 5 (24)
Edoxaban 6 (6) 2 (10)
Rivaroxaban 54 (54) 9 (43)
Last DOAC intake, h, 
median (IQR)c 
10 (6-16) 10 (8-18)
DOAC levels, median (IQR)d 
Apixaban 163 (63-193) 219 (151-219)
Dabigatran 118 (9-133) 42 (8-42)
Edoxaban 163 (128-163) 62 (17-62)
Rivaroxaban 121 (63-279) 138 (84-435)
Concomitant antiplatelet, n (%)
Acetylsalicylic acid 3 2 (10)




Abbreviations: DOAC, direct oral anticoagulant; eGFR, estimated 
glomerular filtration rate; IQR, interquartile range; SD, standard 
deviation.
aWeight was missing in 28 patients. 
be-GFR was measured by the formula of Chronic Kidney Disease 
Epidemiology Collaboration and was missing in 5 patients. 
cFor major bleeding: n=51, for urgent intevention: n=15. 
dn = 5 for apixaban, n = 10 for dabigatran, n = 2 for edoxaban, n = 25 for 
rivaroxaban. 
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Site of the bleeding, n (%)
Gastrointestinal 27 (27) 21 (28) 6 (24)
Intracranial 60(59) 45 (59) 15 (60)
Other 14(14) 10 (13) 4 (16)
Bleeding due to trauma, n (%) 37 (39) 28 (37) 9 (36)
Hemoglobin at presentation (mmol/L), mean 
(SD)
7.0 (2.1) 7.0 (2.1) 7.3 (1.3)
Presentation severity, n (%)d 
Category 1 1 (1) 1 (1) 0
Category 2 16 (16) 12 (16) 4 (16)
Category 3 78 (77) 58 (76) 20 (80)
Category 4 6 (6) 5 (7) 1 (4)
Administration of reversal agent, n (%) 68 (67) 51 (67) 17 (68)
PCC, n (%) 54 (54) 51 (67) 3 (12)
Total dose PCC, IU/kg, median (IQR) 3500 (3000-4000) 3500 (3000-4000) 3000 (NA)
Dose of PCC, IU, median (IQR) 50 (37.5-50) 50 (46-50) 28 (NA)
Idarucizumab, n (%) 16 (16) 1 (1) 16 (64)
Dose of idarucizumab, g, median (IQR) 5 (5-5) 5 (NA) 5 (5-5)
Dose of idarucizumab, median (IQR) 5 (5-5) 5 (NA) 5 (5-5)
Tranexamic acid, n (%) 15 (15) 12 (16) 3(12)
Fresh frozen plasma, n (%) 5 (5) 4 (5) 1 (4)
Procedure to control bleeding, n (%)
Surgical intervention 18 (18) 13 (17) 5(20)
Endoscopic intervention 20 (20) 16 (21) 4(16)
Radiologic intervention 2 (2) 1 (1) 1(4)
Other 1 (1) NA 1(4)
Erythrocytes transfusion, n (%) 31 (31) 23 (30) 8 (32)
≤2 units 10 (10) 8 (11) 2(8)
>2 units 20 (20) 14 (18) 6(24)
Platelet transfusion, n (%) 7 (7) 7 (9) 0 (0)
Clinical course
Duration of hospitalization, mean (SD) 7 (3-14) 10 (9) 10 (11)
ICU admission, n (%) 35 (37) 25 (33) 10 (40)
Duration ICU admission, d, mean (SD) 2.4 (5.4) 2.3 (5.3) 2 (5)
Clinical course severityd 
Category 1, n (%) 5 (5) 3 (4) 2 (8)
Category 2, n (%) 36 (36) 26 (34) 10 (40)
Category 3, n (%) 47 (47) 39 (51) 8 (32)
Category 4, n (%) 3 (3) 6 (8) 4 (16)
Not assessable 0 0 1
Abbreviations: ICU, intensive care unit; IQR, interquartile range; NA, not applicable; SD, standard deviation.
aSystolic blood pressure was missing in 8 patients. 
bPulse was missing in 11 patients. 
cWas missing in 5 patients. 
dSubclassification for ISTH major bleeding according to the severity of bleeding, previously described in methods section of this paper. 
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PCC as a reversal agent. Surgical effective hemostasis was achieved 
in all 14 patients (100%; 95% CI, 79%-100%) (Table 6). Of the 14 pa-
tients, 1 (7%; 95% CI, 1%-32%) patient passed away within 30 days, 
including 1 (7%; 95% CI, 1%-32%) patient on rivaroxaban for AF who 
died from an ischemic stroke 7 days after administration of PCC in a 
dose of 50 IU/kg; it is unclear whether anticoagulation had been re-
sumed. This was the only thromboembolic event corresponding with 
a 30-day thromboembolic rate of 7% (95% CI, 1%-32%).
Of the 2 patients who did not receive PCC, 1 (50%; 10%-91%) 
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Abbreviations: FXa-I, factor Xa inhibitor; PCC, prothrombin complex concentrate.
aDue to transfer to other hospitals, effective hemostasis could not be assessed in 5 patients; all 5 
were in the PCC group. 
bTwo patients received both idarucizumab and PCC as a reversal agent, and 1 patient only received 
PCC for dabigatran reversal. The patient's outcomes are not presented in this table but are 
described in the text. 









Urgent intervention, n (%)
Surgery 11 (52) 8 (50) 3 (60)
Other procedure 10 (48) 8 (50) 2 (40)
Administration of reversal agent 19 (91) 14 (88) 5 (100)
PCC, n (%) 14 (67) 14 (88) 0
Dose of PCC, IU, median (IQR) 2500 (1438-4000) 2500 (1438-4000) NA
Total dose PCC, IU/kg, median 
(IQR)
45 (25-50) 45 (25-50) NA
Idarucizumab, n (%) 5 (24) 0 5 (100)
Dose of idarucizumab, g, median 
(IQR)
5 (5-5) NA 5 (5-5)
Erythrocytes transfusion, n (%) 3 (14) 1 (6) 2 (40)
≤2 units 1 (5) NA 1 (20)
>2 units 2 (10) 1 (6) 1 (20)
Specification urgent intervention during course
Duration of hospitalization, 
mean (SD)
18 (12) 11 (7-30) 30 (16-32)
ICU admission, n (%)a  12 (60) 9 (56) 3 (60)
Duration of ICU admission, d, 
mean (SD)
6 (10) 5 (3-18) 4 (4-6)
Abbreviations: FXa-I, factor Xa inhibitor; IQR, interquartile range; NA, not applicable; PCC, 
prothrombin complex concentrate; SD, standard deviation.
a1 missing value. 
TA B L E  5   Details of urgent 
interventions
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surgical procedure, 3 days after anticoagulation was resumed. The 
other patient died within 1 day after admission; the death was due 
to sepsis. No thromboembolic events were reported.
3.2.2 | Urgent intervention while on dabigatran
All 5 (100%) patients presenting with an indication for urgent interven-
tion while on dabigatran were treated with idarucizumab before the in-
tervention took place. Surgical effective hemostasis rate was achieved 
in all patients (100%; 95% CI, 57%-100%) (Table 6). No thromboem-




We were able to collect samples for analysis of anti-Xa levels in 30 
patients (30%) using FXa-I and dabigatran levels in 7 patients (7%) 
taking dabigatran who presented with major bleeding. Of the 30 
patients in whom anti-Xa levels were measured, 5 (17%) had anti-
Xa levels <50 ng/mL, and of the 7 patients in whom dabigatran 
levels were measured, 2 (29%) had dabigatran levels <50 ng/mL. 
Rivaroxaban levels in samples taken at presentation (n = 24) ranged 
between 0 and 542 ng/mL, apixaban levels (n = 4) ranged between 
38 and 200 ng/mL, and edoxaban levels (n = 2) ranged between 128 
and 197 ng/mL. Patients on dabigatran (n = 7) had plasma levels from 
1 to 240 ng/mL. Median drug levels are presented in Table 2.
Urgent interventions
In patients who presented with an indication for urgent intervention 
while on a DOAC, we were able to collect samples for analysis of anti-
Xa levels of 9 (43%) patients taking FXa-I and dabigatran levels in 2 
(40%) patients taking dabigatran. Of the 9 patients in whom anti-Xa 
levels were measured, 2 (22%) were <50 ng/mL, and of the 2 patients 
in whom dabigatran levels were measured, 1 (50%) was <50 ng/mL. 
Rivaroxaban levels in samples taken at presentation (n = 5) ranged be-
tween 30 and 452 ng/mL, apixaban levels (n = 2) and edoxaban levels 
(n = 2) ranged between 151 and 286 ng/mL and 17 and 106 ng/mL, 
respectively. Patients on dabigatran (n = 2) had plasma levels from 8 to 
75 ng/mL.30 Median drug levels are presented in Table 2.
3.3.2 | Baseline thrombin generation in patients with 
DOAC-related emergencies
Figure 1A shows the tissue factor–triggered thrombin generation (CAT 
assay) in samples from DOAC-treated patients (patients with bleeding 
and urgent interventions combined) in comparison to the healthy volun-
teers. Lag time showed a significant (P < .0001) prolongation in almost 
all samples up to 700% of normal. DOAC level was plotted against CAT 
lag time in Figure 1B. The ETP between samples from DOAC-treated pa-
tients and healthy volunteers at baseline showed no significant difference 
for both FXa-I– (P = .06) and dabigatran- (P = .09) treated patients. The 
thrombin peak was significantly reduced in patients on a FXa-I (P < .0001) 
but not in those on dabigatran (P = .75). CLT was abrogated in 8 samples 
from patients on tranexamic acid (CLT > 3 hours). CT, in accordance with 
CAT lag time, was clearly prolonged in both FXa-I and dabigatran samples 
(P = .004) (Figure 1A). In the analyzed DOAC samples, clot stability varied 
from slightly reduced to enhanced in comparison with the control plasma. 
Most patients, however, had a CLT within the normal range (Figure 1A).
3.3.3 | Thrombin generation in patients treated with 
PCC for a FXa-I–related major bleeding
We obtained plasma from 19 (37%) of 51 patients receiving PCC for 
treatment of major bleeding. In Figure 2, parameters for thrombin 
generation (lag time, peak thrombin generation, ETP), CT, and CLT are 
shown for the 19 patients receiving PCC in management of bleeding. 
Immediately after administration of PCC, laboratory analysis showed 









agent (n = 2)
Idarucizumab 
(n = 5)
Primary outcome, n (%, 95% CI)








Safety outcomes, n (%, 95% CI)






30-d thromboembolic rate 1
(7, 1-32)
0 0
Abbreviations: CI, confidence interval; FXa-I, factor Xa inhibitor; PCC, prothrombin complex 
concentrate.
TA B L E  6   Outcomes of urgent 
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We obtained samples at time points T0 and T1 in 13 patients and the 
full series of samples (T0, T1, and T2) in 9 patients. Mean ETP val-
ues increased with 96% immediately after PCC administration from 
1108 nM.Min at T0 to 2275 nM.Min at T1 (P = .001) with 2 patients 
(18%) at T0 and 11 patients (79%) at T1 exceeding the upper limit 
of the ETP reference range. Mean (SD) ETP at T2 was 2539 (699) 
nM.Min (n = 14). For peak thrombin (n = 13), comparable results were 
observed with an increase of 113% from T0 to T1 (P = value .001). For 
CLT analysis (n = 9), mean values increased significantly from T0 to T1 
(P = .014), indicating more stable clots after the administration of PCC.
3.4 | Association between clinical and 
laboratory outcomes
We did not observe differences in anti-Xa levels or thrombin gen-
eration parameters between patients with or without effective 
hemostasis at any time point. This is illustrated by the wide distri-
bution of laboratory values in Figure 2, in which gray circles repre-
sent patients with effective hemostasis and black circles represent 
patients with poor hemostasis. Laboratory values, stratified for 
effective hemostasis, are presented in more detail in Figure 3. The 
thrombin generation parameters of the patient who developed 
VTE 10 days after administration of PCC did not exceed the refer-
ence range of ETP or peak thrombin for nonanticoagulated healthy 
volunteers.
4  | DISCUSSION
In this study, 67% of patients presenting with DOAC-related 
major bleeding achieved effective hemostasis. For patients with 
a FXa-I–related major bleeding (n = 76), two thirds of the patients 
received PCC as a hemostatic agent and effective hemostasis was 
F I G U R E  1   A, Coagulation parameters in DOAC-treated patients at presentation. Patients on FXa-I: rivaroxaban, n = 25 (green circles); 
apixaban, n = 9 (blue squares); edoxaban, n = 4 (red upward triangles). Patients on dabigatran, n = 10 (dark red downward triangles). Open 
circles, urgent intervention patients. Closed circles, patients presented with major bleeding. The 2.5th-97.5th percentile interval for normal 
plasma samples (n = 40 for thrombin generation and n = 24 for the fibrin generation & clot lysis test) is represented as a gray bar. B, CAT lag 
time as function of DOAC concentration. The data are expressed as a percentage of the average normal value. CAT, calibrated automated 
thrombography (tissue factor–triggered thrombin generation); CLT, clot lysis time; CT, clotting time; ETP, endogenous thrombin potential; 
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F I G U R E  2   Coagulation parameters in patients with a FXa-I–related major bleeding treated with PCC. Plasma samples were taken at 
presentation (T0), 15-30 minutes after administration of PCC (T1) and 4-8 h after presentation (T2). Patients with effective hemostasis 
are represented as green circles, and those with poor hemostasis are in red. Clot lysis evaluation was omitted in samples from patients on 
tranexamic acid. Upper graphs: absolute value of assay parameter with dotted lines delimiting the 2.5th-97.5th percentile interval for normal 
plasma samples (n = 40 for thrombin generation and n = 24 for the fibrin generation and clot lysis test). Bottom graphs: data represented as 
ratio of T0 value. FXa-I, factor Xa inhibitor; PCC, prothrombin complex concentrate
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F I G U R E  3   Median thrombin 
generation parameters for patients 
on FXa-Is at different time points, 
stratified by effective hemostasis. The 
main horizontal line represents the 
median value and the lower and upper 
limit represent the interquartile ranges. 
Patients with effective hemostasis are 
represented as green circles and those 
with poor hemostasis are in red. FXa-I, 
factor Xa inhibitor
p = 0.21 p = 0.20 p = 0.80
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70% (95% CI, 55%-81%) in those patients. Taking into considera-
tion the low observed thromboembolism (2%; 95% CI, 0.3%-10%) 
incidence within 30 days, a high-dose PCC could be a reasonable 
option for FXa-I–related major bleeding, with laboratory samples 
confirming a swift increase in thrombin generation after admin-
istration of PCC. For the patients with dabigatran-related major 
bleeding (n = 25), 64% received idarucizumab as a reversal agents 
and effective hemostasis was 75% (95% CI, 51%-90%) in those 
patients. DOAC blood levels varied widely at presentation of the 
emergency, but did not seem to be associated with the clinical 
outcome.
Of the patients presenting with the need for an urgent in-
tervention while on a DOAC (n = 21), 95% achieved surgical ef-
fective hemostasis. For the patients with the need for an urgent 
intervention while on a FXa-I (n = 16), PCC was administered in 
14 (88%) patients. Effective surgical hemostasis was achieved in 
all 14 patients receiving PCC. Idarucizumab was administered in 
all 5 patients presenting with the need for an urgent intervention 
while on dabigatran and all patients achieved effective surgical 
hemostasis.
The observed 70% effective hemostasis and the low thrombo-
embolic events rate in the group with FXa-I–related major bleeding 
receiving PCC is in line with previous findings of other prospective 
cohort studies showing a pooled effective hemostasis rate of 69% 
(95% CI, 61%-76%) according to the ISTH definition.21,22
The results of the present study can also be related to the tri-
als that led to regulatory approval of PCC for VKA reversal, idaru-
cizumab for dabigatran reversal, and andexanet alfa for apixaban 
and rivaroxaban reversal.13,23,31 In the single-armed study leading to 
approval of idarucizumab for reversal of dabigatran (REVERSE-AD), 
effective hemostasis was not determined. However, 68% of the 
patients had confirmed bleeding cessation within 24 hours.13 In 
the trial leading to approval of PCC for reversal of VKA and in the 
single-armed cohort study leading to approval of andexanet alfa 
(ANNEXA-4) for specific reversal of FXa-I, effective hemostasis 
was achieved in 72% and 82%, respectively.23,31 The achieved 70% 
(95% CI, 55%-81%) effective hemostasis in our patients managed 
with PCC for FXa-I related major bleeding is in line with those stud-
ies.13,23,31 Thromboembolic events occurred in 4.8% of the patients 
in the REVERSE-AD cohort, in 7.8% of the patients in trial leading to 
approval of PCC for reversal of VKA in the United States, and in 10% 
of the patients in the ANNEXA-4 cohort. Our observed 2% (95% CI, 
0.3%-10%) thromboembolic rate is, again, in line with those studies. 
In this study, we did not account for the competing risk of death 
for thrombosis, and this may have led to an underestimation of the 
thromboembolic events.
The 30-day mortality of DOAC emergencies was substantial, 
irrespective of the bleeding management, which could partially be 
explained by the large proportion of intracranial hemorrhages in 
this cohort. This incidence is again in line with other oral anticoag-
ulation–related major bleeding cohorts managed with their specific 
reversal agents. This likely suggests that most harm of the bleeding 
occurs before presentation at the hospital in a large proportion of 
patients with oral anticoagulant–related major bleeding. The mor-
tality benefit of any reversal strategy is limited in those patients and 
reinforces the demand for a randomized controlled trial to under-
stand the additional value of any reversal agent on top of supportive 
measures.13,23,31
Our observed surgical effective hemostasis rate after treatment 
with PCC is high and similar to the rate observed in an Israeli retro-
spective study in which they included more severe urgent interven-
tions than we did in our cohort.32 Thromboembolic and mortality 
rates at 30 days are similar. However, when making this indirect 
comparison, it needs to be kept in mind that for both cohorts differ-
ent definitions for the primary outcome effective hemostasis were 
applied.32
Of interest, in spite of similar effective hemostasis and throm-
boembolism, the median administered dose of PCC in our cohort 
was twice as high (50 vs. 25 IU/kg) than in the other 2 cohorts re-
porting effective hemostasis.21,22 This raises important questions 
on the optimal PCC dose. The rationale for our dose was based 
on studies in healthy volunteers who received PCC at the time of 
expected peak blood levels. In these studies only a 50 IU/kg dose 
of PCC fully restored ETP, whereas doses of 25 and 37.5 IU/kg 
increased ETP but not to preanticoagulation levels.16 In contrast 
to the healthy volunteers study, most patients in this cohort re-
ceived PCC well after the expected peak blood level, at which time 
a lower than 50 IU/kg dose may be sufficient. Moreover, it needs 
to be taken into account that in all 3 of these studies in bleeding 
patients other hemostatic measures, along with administration of 
PCC, were also taken. If PCC will continue to be used as a hemo-
static agent for FXa-I–related emergencies, further studies into 
the optimal PCC dosing is warranted.
Parameters of thrombin generation, mainly lag time and peak 
thrombin, show significant differences in patients treated with 
DOACs compared with normal subjects with lag time as the most 
sensitive parameter. Moreover, in patients treated with PCC for 
FXa-I emergencies, our results demonstrate a correction in throm-
bin generation parameters after administration, particularly in peak 
thrombin and ETP, confirming the results of in vitro experiments as 
well as studies in healthy nonbleeding volunteers.16,33,34. Increased 
thrombin generation after PCC administration coincided with in-
creased clot stability (elongated CLT), in accordance with previous 
in vitro observations.29 These findings are difficult to interpret as 
the effect of bleeding on thrombin generation is unknown and as a 
universal reference range for thrombin generation has never been 
established. Our results do not suggest a relationship between these 
coagulation indices and severity of bleeding or complications. It may 
be so that such coagulation tests cannot sufficiently reflect local he-
mostasis at the site of injury, or this finding could be a consequence 
of the lack of validation of our primary outcome, as stated below. 
Future research in a larger setting should investigate the role of co-
agulation parameters for management and predicting outcomes of 
DOAC-related bleeding.
The observational design of this study is the main limitation 
for the interpretations of our results. As the management of these 
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patients was left to the discretion of the treating physician, clinical 
outcomes were subject to confounding by indication. Therefore, we 
made no head-to-head comparison between the patients who re-
ceived PCC and the ones who did not. Nevertheless, this design is 
inherent to the study subject as reversal agent studies tend to be sin-
gle-arm studies and have never been compared to placebo before.13,31 
Second, there are some limitations regarding the applied ISTH defi-
nition for effective hemostasis. Most importantly, this definition is a 
clinical score and has some subjective elements, such as evaluation of 
neurological scoring (intracerebral bleeding) or evaluating of pain and 
swelling (musculoskeletal bleeding). Furthermore, other aspects, such 
as the hemoglobin drop over time, lack specificity and are influenced 
by other factors than cessation of bleeding such as hydration status 
at presentation. Nevertheless, a validation study of this score demon-
strated acceptable interobserver reliability, and the interpretation of 
the score (effective vs ineffective hemostasis) had substantial agree-
ment with the subjective clinical opinion of the treating physician. 
Therefore, in spite of these limitations, the ISTH definition probably 
remains the best score to evaluate the outcome of major bleeding.35
Additionally, the limited sample size leads to lack of statistical 
power, which precludes multivariate regression analysis for determi-
nants that independently predict effective hemostasis or thrombo-
embolism, including the use of hemostatic agents. Finally, we cannot 
rule out a selection bias in this cohort, as we would have expected 
more gastrointestinal bleeding for a consecutively including cohort 
and may have missed some patients with gastrointestinal bleeding 
that were not notified to the study team. Along with the potential 
selection bias, the fact that 4 of the 5 participating centers are ac-
ademic neurological centers likely explains the high proportion of 
intracranial bleeding in our cohort.
Our study further supports that PCC, in addition to other he-
mostatic measures, leads to substantial proportions of effective 
hemostasis and may possibly be effective in the management of 
FXa-I–related major bleeding or urgent interventions. We believe 
PCC is safe due to the low observed thromboembolic incidence; 
however, we acknowledge the high mortality rate and the need for 
further exploration on the reasons for death, before classifying PCC 
as a safe agent. Whether the results obtained with PCC are similar to 
those obtained by the specific reversal agent andexanet alfa would 
need to be answered by a randomized controlled trial. Regulatory 
approval of andexanet alfa by the FDA and EMA was conditional 
upon further studies into efficacy and safety of reversal of FXa-
I.14,36 Currently, a randomized controlled trial investigating the 
efficacy and safety of andexanet alfa compared to usual care for 
patients presenting with a FXa-I–related intracranial hemorrhage, 
is recruiting and will inform the medical community which strategy 
should best be used in the management of FXa-I related emergen-
cies (trialregister.gov; NCT03661528).
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